Next Article in Journal
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895
Next Article in Special Issue
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors
Previous Article in Journal
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
 
 
Review

Article Versions Notes

Curr. Oncol. 2023, 30(5), 5024-5046; https://doi.org/10.3390/curroncol30050379
Action Date Notes Link
article pdf uploaded. 15 May 2023 16:07 CEST Version of Record https://www.mdpi.com/1718-7729/30/5/379/pdf-vor
article xml file uploaded 17 May 2023 05:19 CEST Original file -
article xml uploaded. 17 May 2023 05:19 CEST Update https://www.mdpi.com/1718-7729/30/5/379/xml
article pdf uploaded. 17 May 2023 05:19 CEST Updated version of record https://www.mdpi.com/1718-7729/30/5/379/pdf
article html file updated 17 May 2023 05:20 CEST Original file https://www.mdpi.com/1718-7729/30/5/379/html
Back to TopTop